Department of Neurosurgery, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Curr Oncol Rep. 2023 May;25(5):479-489. doi: 10.1007/s11912-023-01380-x. Epub 2023 Feb 28.
This review will discuss the challenges facing chimeric antigen receptor (CAR)-T cell application for solid tumors and opportunities to overcome these obstacles. In addition, this review will examine therapies that are in development for pediatric solid tumors.
The similar success of CAR-T cell treatment for hematological malignancies has not been observed in solid tumors because of the hostile tumor microenvironment and tumor heterogeneity. Most strategies developed to combat these limitations emphasize combinatorial techniques that still require further testing. Preliminary results of multiple clinical trials, including GD2- and HER2-CAR-T cells, are encouraging but must be reproduced and validated on a larger scale. CAR-T cell application in solid tumors remains challenging, and most research is in development. Several clinical trials are ongoing for pediatric solid tumors. Early results are promising but demonstrate the need for CAR-T cell modification to prevent tumor recurrence.
本篇综述将讨论嵌合抗原受体（CAR）-T 细胞应用于实体瘤所面临的挑战，以及克服这些障碍的机会。此外，本篇综述还将探讨针对小儿实体瘤的正在开发中的疗法。
CAR-T 细胞治疗血液恶性肿瘤的相似成功并未在实体瘤中观察到，这是由于恶劣的肿瘤微环境和肿瘤异质性所致。为了应对这些限制，大多数开发的策略都强调组合技术，这些技术仍需要进一步测试。包括 GD2 和 HER2-CAR-T 细胞在内的多项临床试验的初步结果令人鼓舞，但必须在更大规模上进行复制和验证。CAR-T 细胞在实体瘤中的应用仍然具有挑战性，大多数研究仍处于开发阶段。针对小儿实体瘤的几项临床试验正在进行中。早期结果令人鼓舞，但也表明需要对 CAR-T 细胞进行修饰以防止肿瘤复发。
